Clinical ophthalmology · 2023 · 14 citations · 36 references
MedicineOphthalmologyPharmacotherapyAllergyHypersensitivityOcular DiseaseAllergic ConjunctivitisConjunctival PathologyOcular AllergyOcular TolerabilityOphthalmic OintmentsTopical Ophthalmic MedicationsAllergic Conjunctivitis ManagementAllergic Conjunctivitis PharmacotherapyConjunctival Impression CytologyConjunctivitis TreatmentHistopathological ToxicityOcular Surface Drug ToxicityOcular SymptomsTopical Ocular Medication Toxicity
Purpose: To study the efficacy and toxic effects of bepotastine besilate 1.5% preservative-free (BB-PF) and olopatadine 0.2% BAK-preserved (OL-BAK) drops on the ocular surface of patients with allergic conjunctivitis. Patients and Methods: Ninety-seven patients with allergic conjunctivitis diagnosis participated in a prospective, multicenter, randomized, double-blind, controlled, parallel-group clinical trial. Patients received either BB-PF (n=48) or OL-BAK (n=49), both administered once daily in the morning. The patients were followed for 60 days. Ocular itching was the primary outcome measure. Secondary outcomes included ocular symptoms, signs, and non-ocular symptoms associated with rhinoconjunctivitis. Conjunctival impression cytology (CIC) was performed to evaluate histopathological changes related to the toxic effects of preservatives. Results: BB-PF treatment was associated with a 1.30 more probability of diminished ocular itching than OL-BAK (odds ratio (OR)=1.30; 95% CI=(0.96-1.7); p=0.086). No statistically significant differences were found between treatments in the resolution of other ocular symptoms or signs, except for tearing, which was superior in the BB-PF (OR=1.37; 95% (1.26-1.47); p<0.0001). BB-PF was superior in terms of the resolution of rhinorrhea (p=0.040) and nasal itching (p=0.037). After 60 days of treatment, the BB-PF group exhibited 2.0 times higher probability of having a lower Nelson scale score compared to the OL-BAK group (OR=2.00; 95% CI=(1.19-3.34); p=0.010). Conclusion: Both medications presented a similar efficacy in terms of the resolution of ocular signs and symptoms associated with ocular conjunctivitis. BB-PF is superior in the resolution of non-ocular symptoms and safer for the ocular surface than OL-BAK.
36
Preservatives in eyedrops: The good, the bad and the ugly
Christophe Baudouin, Antoine Labbé, Hong Liang et al. · Progress in Retinal and Eye Research · 2010 · 1.1K citations
Ocular surface inflammatory changes induced by topical antiglaucoma drugs
Christophe Baudouin, Pierre‐Jean Pisella, Kathleen Fillacier et al. · Ophthalmology · 1999 · 393 citations